HexaPro - Vaxxas
Alternative Names: HexaPro HD-MAP vaccine; HexaPro SARS-COV2 Vaccine; SARS-CoV-2 Spike VaccineLatest Information Update: 28 Dec 2025
At a glance
- Originator University of Texas at Austin
- Developer Griffith University; University of Queensland
- Class COVID-19 vaccines; Subunit vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in Australia (Transdermal, Patch)
- 28 Mar 2025 Vaxxas has patent protection for high-density microarray patch (HD-MAP) vaccination technology in Europe, Asia and Australia
- 28 Mar 2025 Vaxxas completes a phase I trial in COVID-19 infections (Prevention) in Australia (Transdermal) before March 2025